Chief Scientific Officer
Dr. Ma is a leader in genomic research and molecular diagnostics for personalized medicine. Applying his multi-disciplinary expertise in molecular biology, bioinformatics and statistics, Dr. Ma has a proven track record of developing molecular signatures for cancer diagnostics and identifying novel drug targets for over 14 years. Prior to joining ACD, Dr. Ma was Vice President of R&D/Biostatistics in bioTheranostics (formerly AviaraDx and Arcturus Bioscience), a bioMérieux company, where he led efforts to successfully develop several advanced molecular diagnostic tests in cancer classification and prognosis. Prior to bioTheranostics, Dr. Ma held senior bioinformatics positions at Johnson & Johnson Pharmaceutical Research Institute and Monsanto/Searle. He received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.
Chief Financial Officer
Jessie Wang brings to ACD over 15 years of broad financial management experience. Starting from 2011, she has consulted with multiple start-up companies, helping them successfully raise funds from top tier venture capital firms, venture debt and complete financial audits. Prior to that, Jessie held various managerial positions including VP Controller since 2005 at Symyx Technologies, Inc., where she developed her expertise in SEC reporting, merger and acquisition, internal control, stock plan administration and revenue recognition. Jessie Wang obtained her public accounting training from PricewaterhouseCoopers and Moss Adams after she received her MBA from California State University, Hayward and her BS in Management Science degree from Fudan University, China.
Chief Medical Officer
Dr. Rob Monroe brings to ACD a record of success providing medical leadership for both venture-backed and public companies in the clinical diagnostics industry. Most recently, he served as Medical Director and Vice President of Laboratory Operations for Veracyte (VCYT), a diagnostics company focused on molecular cytology, where he led the company’s CLIA laboratories, including oversight of the highly successful Afirma® Thyroid FNA Analysis and recent launch of the Percepta™ Bronchial Genomic Classifer. Prior to Veracyte, Dr. Monroe served as Chief Medical Officer of BioImagene (acquired by Ventana, a member of the Roche Group, in 2010), a leading provider of imaging solutions for anatomic pathology and clinical diagnostics where he headed the company’s efforts to develop software applications for pathologists, including multiple FDA-cleared algorithms for immunohistochemistry analysis. Dr. Monroe was also Co-Founder and Chief Medical Officer of OncoMDx, a Palo Alto-based molecular diagnostics laboratory later acquired by CORE Diagnostics to support expansion of next generation diagnostics in India. Prior to joining BioImagene, Dr. Monroe served as a Medical Director for Central Coast Pathology where he led cytopathology and molecular pathology programs. Dr. Monroe is board certified in anatomic pathology, clinical pathology, and cytopathology. He holds MD and PhD degrees from Harvard Medical School and completed his pathology training at Stanford and UCLA.
VP, Business Development
Dr. Bunker brings ten years of experience in business development with pharmaceutical/biotechnology organizations. Prior to joining ACD, Dr. Bunker was Director of Business Development at Cell Signaling Technology, Inc. (CST), where he helped build the company from its initial spin-out to a $100M business. Before CST, Dr. Bunker pursued cancer research at Genome Therapeutics Corp. Dr. Bunker received a Ph.D in Biological Chemistry from Harvard University and a M.B.A. from the executive program of Boston University. He received post-doctoral training in cancer molecular biology at University of California, San Francisco.
